Overview

Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting

Trial end date:
2025-01-22

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, and non-randomized Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-24714 as monotherapy and in combination with chemotherapy in participants with advanced or metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Treatments:

Paclitaxel